RXRX Recursion Pharmaceuticals, Inc. Class A Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:45
Aug 25
Aug 25
Recursion is a pure-play TechBio platform where clinical validation of a single lead asset or a major licensing deal could drive a 5-10x re-rating from its current sub-$2B valuation.
HIGH
18:33
Aug 23
Aug 23
Author lists 40 tickers across sectors to watch on Monday.
Author lists 40 tickers across sectors to watch on Monday, expecting some to rally and others to pull back, but frames it as monitoring rather than taking positions.
LOW
14:27
Aug 23
Aug 23
Author highlights five biotech stocks as top picks following an AI-driven breakthrough.
Author highlights five biotech stocks as top picks following an AI-driven breakthrough in biotech, but frames them as names to watch with theses coming soon, not explicit positions.
LOW
15:41
Aug 18
Aug 18
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not.
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not explicitly held, making ABCL a clear long and the others watch.
LOW
01:17
Aug 18
Aug 18
Author expresses hope that RXRX and PRME follow ABCL's trajectory but offers no position.
Author expresses hope that RXRX and PRME follow ABCL's trajectory but offers no position or explicit forward call, so both are watch.
LOW
23:45
Aug 13
Aug 13
Recursion Pharmaceuticals has failed.
Cramer did not like the Recursion Pharmaceuticals CEO's story, notes the stock has been a failure after an equity offering, and wishes the CEO had not come on the show.
MED
23:52
Aug 12
Aug 12
The company must produce results over losses.
The company is only generating losses and needs to produce tangible results soon to justify investment.
MED
19:16
Aug 10
Aug 10
The author expresses a preference for these three biotech names over the parent's picks.
The author expresses a preference for these three biotech names over the parent's picks, but without stating a position or forward-looking call, so they are indexed as watch.
LOW
13:40
Aug 05
Aug 05
Roche advances the first project from its AI drug-discovery partnership with Recursion.
Roche advances the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.
11:56
Jun 30
Jun 30
Speaker presents this as a top pick with bullish catalysts (clinical signals, pipeline, chart).
Speaker presents this as a top pick with bullish catalysts (clinical signals, pipeline, chart), no personal position stated.
MED
14:55
Jun 24
Jun 24
Author expresses a general like for RXRX in a biotech bull run context but does not state.
Author expresses a general like for RXRX in a biotech bull run context but does not state a position or explicit forward call.
LOW
15:52
Jun 20
Jun 20
The author shares their favorite biotech stocks with AI-driven drug discovery and gene editing.
The author shares their favorite biotech stocks with AI-driven drug discovery and gene editing platforms but frames them as personal favorites without an explicit forward-looking position or trade call.
10:01
Jun 05
Jun 05
Avoid RXRX — speaker explicitly rejected it after due diligence.
Avoid RXRX — speaker explicitly rejected it after due diligence, citing inferior fundamentals versus ABCL and warning that buyers will suffer consequences; implicit strong caution against entry.
MED
23:33
Jun 04
Jun 04
Speaker states personal due diligence on RXRX was unsatisfactory.
Speaker states personal due diligence on RXRX was unsatisfactory, expressing skepticism without a specific deterioration mechanism or trade direction.
LOW
13:24
Jun 01
Jun 01
The author discloses a numbered portfolio of 11 current long positions by size and a separate.
The author discloses a numbered portfolio of 11 current long positions by size and a separate focus list of 18 tickers for watchlist monitoring, expressing gratitude to followers for supporting his full-time trading career dream.
LOW
23:52
May 13
May 13
Watch RXRX for vertical AI biotech; NVIDIA's exit reduces near-term catalyst but platform.
Watch RXRX for vertical AI biotech; NVIDIA's exit reduces near-term catalyst but platform persists.
HIGH
11:00
Apr 23
Apr 23
One detailed comment (+5) notes RXRX has short interest 37% of float, days to cover 10.6, and institutional ownership 56% – a setup that could produce a squeeze if volume and a catalyst appear. While only a single comment, the data‑driven analysis provides a credible basis for monitoring. The community may not have full consensus, but the metrics are compelling. Place RXRX on watchlist; initiate a small long position or buy calls only if high volume and a clear catalyst (e.g., news, breakout above resistance) confirm the squeeze potential. Risks: Squeeze may not materialize; high short interest can also reflect fundamental weakness. No other comments corroborate the thesis.
MED
00:28
Mar 16
Mar 16
RXRX cited as pharma-disruption biotech
Author co-mentions RXRX alongside peers as a biotech company with potential to disrupt the pharma industry; no directional commitment made.
LOW
00:24
Mar 12
Mar 12
These companies are either losing too much money in a tough tape, had bad quarters, failed to deliver on big promises, or are trading like meme stocks. In a macro environment threatened by inflation and oil shocks, the market has zero tolerance for cash-burning, speculative companies. Capital will aggressively rotate out of unprofitable tech and biotech into companies with real earnings and strong balance sheets. AVOID. Do not buy the dip on cash-burning or speculative stocks in a hostile, inflation-wary market. A sudden drop in interest rates or a rapid resolution to geopolitical conflicts could spark a risk-on rally, causing these heavily shorted or beaten-down names to squeeze higher.
13:46
Mar 04
Mar 04
RXRX appoints new CEO
Notes a management change at RXRX with a new CEO, a fundamental event; no directional view stated.
LOW
00:26
Mar 04
Mar 04
Institutional ownership at all-time high
Notes institutional ownership is at an all-time high, no directional view stated.
MED
21:56
Feb 17
Feb 17
Nvidia 13F shows new INTC, SNPS positions
Reports Nvidia's Q4 13F filing showing new positions in INTC, SNPS, and NOK, and exits from ARM, APLD, RXRX, and WRD.
MED
14:12
Aug 10
Aug 10
Exscientia valued at $68M in Recursion merger.
Notes Exscientia's valuation in its merger with Recursion Pharmaceuticals.
LOW
About RXRX Analyst Coverage
Buzzberg tracks RXRX (Recursion Pharmaceuticals, Inc. Class A Common Stock) across 11 sources. 2 bullish vs 0 bearish calls from 11 analysts. Sentiment: predominantly bullish (9%). 23 total trade ideas tracked. Latest voices: Outlier Capital, __con_, caesarcapitalz.